keyword
https://read.qxmd.com/read/39275934/is-using-inhaled-corticosteroid-effective-against-covid-19-pneumonia-severity-and-mortality
#1
JOURNAL ARTICLE
Hatice Kiliç, Emine Argüder, Musa Civak, Emin Gemcioğlu, Ayşe Kaya Kalem, İmran Hasanoğlu, Bircan Kayaaslan, Sibel Günay, Esmehan Akpinar, Habibe Hezer, Ebru Şengül Şeref Parlak, Filiz Sadi Aykan, Yasin Kocaman, Esra Ünsay Metan, Mükremin Er, Aynil Dalkiran, Hülya Çelenk Ergüden, Zeynep Hancioğlu, Emre Altin, Eren Ceylan, Fatma Eser, Adalet Altunsoy Aypak, Esragül Akinci, Selma Karaahmetoğlu, Emra Asfuroğlu Kalkan, Osman Inan, Abdürrezzak Yilmaz, Bağdagül Yüksel Güler, Esra Çopuroğlu, Işıl Özkoçak Turan, Emre Demir, Serhat Hayme, Derya Gökmen, Aziz Ahmet Surel, Ebru Ünsal, Hatice Canan Hasanoğlu, İhsan Ateş, Rahmet Güner, Ayşegül Karalezli
INTRODUCTION: It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia. MATERIALS AND METHODS: The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included...
September 2024: Tüberküloz Ve Toraks
https://read.qxmd.com/read/39275800/pharmacological-strategies-in-dermatomyositis-current-treatments-and-future-directions
#2
REVIEW
Jinqiang Guo, Weiwei Wang, Anbin Huang, Chunli Mei
Dermatomyositis (DM) is a complex and rare autoimmune disease characterized by muscle weakness and distinctive skin rashes. Its pathogenesis involves a combination of genetic susceptibility, environmental triggers, and immunological factors, with interferon pathways and specific gene upregulations playing crucial roles. Diagnosis is based on clinical presentation, laboratory findings, and imaging, with particular emphasis on myositis-specific antibodies and characteristic muscle and skin changes. The clinical heterogeneity of DM, including variants such as clinically amyopathic DM and DM-associated interstitial lung disease, necessitates a personalized diagnostic and therapeutic approach...
September 14, 2024: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://read.qxmd.com/read/39274286/does-a-type-of-inciting-antigen-correlate-with-the-presence-of-lung-fibrosis-in-patients-with-hypersensitivity-pneumonitis
#3
JOURNAL ARTICLE
Kamila Deutsch, Katarzyna B Lewandowska, Agata Kowalik, Iwona Bartoszuk, Piotr Radwan-Röhrenschef, Małgorzata Sobiecka, Małgorzata Dybowska, Witold Z Tomkowski, Monika Szturmowicz
Introduction: Hypersensitivity pneumonitis (HP) is an interstitial inflammatory lung disease that develops as a result of exposition to various, mostly organic antigens. In some patients, fibrotic HP is diagnosed. Factors predisposing to the development of fibrotic lung disease in HP patients are not well documented in the literature. The genetic susceptibility of the patient, type of inciting antigen, and type of exposure, as well as various demographic and clinical variables, may influence the fibrotic process...
August 27, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/39272673/a-systematic-review-of-the-key-predictors-of-progression-and-mortality-of-rheumatoid-arthritis-associated-interstitial-lung-disease
#4
REVIEW
Laura Groseanu, Cristina Niță
BACKGROUND: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is an important extra-articular manifestation of rheumatoid arthritis (RA). Identifying patients at risk of progression and death is crucial for improving RA-ILD management and outcomes. This paper explores current evidence on prognostic factors in RA-ILD. METHODS: We conducted a systematic literature review to examine the impact of clinical, radiological, and histological factors on lung function decline and the survival of RA-ILD patients...
August 28, 2024: Diagnostics
https://read.qxmd.com/read/39272068/assessing-health-related-quality-of-life-in-patients-with-interstitial-lung-diseases
#5
JOURNAL ARTICLE
S Stoltefuß, G Leuschner, K Milger, T Kauke, J Götschke, T Veit, A Lenoir, N Kneidinger, Jürgen Behr
BACKGROUND: The R-Scale-PF was proposed to evaluate the health-related quality of life (HRQoL) in patients with idiopathic pulmonary fibrosis (IPF). We generated a German version of the R-Scale-PF (GR-Scale), representing the first translation of the questionnaire into another language and assessed HRQoL longitudinally in various interstitial lung diseases (ILDs) using the R-Scale-PF scoring system at a specialized ILD centre. METHODS: We have translated the questionnaire in accordance with the WHO translation guidelines and applied it to 80 ILD patients of our department, with follow-ups after 3-6 months, assessing its internal consistency, floor and ceiling effects, concurrent validity, known-groups validity, and its responsiveness to changes over time...
September 13, 2024: BMC Pulmonary Medicine
https://read.qxmd.com/read/39272066/clinical-and-radiological-pattern-of-olaparib-induced-interstitial-lung-disease
#6
JOURNAL ARTICLE
Alexandre Brudon, Dorine Fournier, Frédéric Selle, Emmanuel Seront, Rosa Conforti, Gwenaëlle Veyrac, Aurore Gouraud, Bénédicte Lebrun-Vignes, Antoine Khalil, Gérard Zalcman, Valérie Gounant
BACKGROUND: PARP inhibitors (PARPi) are used in the treatment of ovarian, breast, pancreatic, and prostate cancers. Pneumonitis has been identified as a potential side effect, with a higher meta-analysis-assessed risk for olaparib versus other PARPi. Olaparib-induced interstitial lung disease (O-ILD) was first described within the Japanese population, with few information available for Caucasian patients. METHODS: We performed a retrospective study by pooling data from the French and Belgian pharmacovigilance databases from 2018 to 2022...
September 13, 2024: BMC Pulmonary Medicine
https://read.qxmd.com/read/39271844/trastuzumab-deruxtecan-in-her2-positive-advanced-breast-cancer-with-or-without-brain-metastases-a-phase-3b-4-trial
#7
JOURNAL ARTICLE
Nadia Harbeck, Eva Ciruelos, Guy Jerusalem, Volkmar Müller, Naoki Niikura, Giuseppe Viale, Rupert Bartsch, Christian Kurzeder, Michaela J Higgins, Roisin M Connolly, Sally Baron-Hay, María Gión, Valentina Guarneri, Giampaolo Bianchini, Hans Wildiers, Santiago Escrivá-de-Romaní, Manoj Prahladan, Helen Bridge, Nataliya Kuptsova-Clarkson, Nana Scotto, Sunil Verma, Nancy U Lin
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or retrospective patient cohorts with human epidermal growth factor receptor 2-positive (HER2+ ) advanced/metastatic breast cancer (mBC) and stable or active (untreated/previously treated and progressing) brain metastases (BMs). The phase 3b/4 DESTINY-Breast12 study investigated T-DXd in patients with HER2+ mBC and is, to our knowledge, the largest prospective study of T-DXd in patients with BMs in this setting. Patients (stable/active BMs (n = 263) and no BMs (n = 241)) treated with one or more prior anti-HER2-based regimens received T-DXd (5...
September 13, 2024: Nature Medicine
https://read.qxmd.com/read/39271538/bronchoalveolar-lavage-fluid-analysis-in-patients-with-checkpoint-inhibitor-pneumonitis
#8
JOURNAL ARTICLE
Ruxuan Chen, Yujie Shi, Nan Fang, Chi Shao, Hui Huang, Ruili Pan, Yan Xu, Mengqi Wang, Xiangning Liu, Kai Xu, Rui Zhu, Mengzhao Wang
BACKGROUND: Checkpoint inhibitor pneumonitis (CIP) is a relatively uncommon but potentially life-threatening immune-related adverse event (irAE). Lung biopsies have not been commonly performed for CIP patients. Bronchoalveolar lavage fluid (BALF) analysis is a useful diagnostic approach for interstitial lung disease. However, BALF features were inconsistent across different studies. METHODS: We retrospectively reviewed the medical records of 154 patients with pathologically confirmed malignancies and suffering from CIPs between July 2018 and December 2022...
September 13, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/39271165/novel-deep-learning-analysis-for-connective-tissue-disease-related-interstitial-lung-disease-extent-assessment-on-ct-a-preliminary-cross-sectional-study
#9
JOURNAL ARTICLE
Yuhei Ito, Yasutaka Ichikawa, Shuichi Murashima, Hajime Sakuma, Tae Iwasawa, Yoshiyuki Arinuma, Ayako Nakajima
OBJECTIVES: Physician's evaluation of interstitial lung disease (ILD) extension with high-resolution computed tomography (HRCT) has limitations such as lack of objectivity and reproducibility. This study aimed to investigate the utility of computer-based deep-learning analysis using QZIP-ILD® software (DL-QZIP) compared with conventional approaches in connective tissue disease (CTD) -related ILD. METHODS: Patients with CTD-ILD visiting our Rheumatology Centre between December 2020 and April 2024 were recruited...
September 13, 2024: Rheumatology
https://read.qxmd.com/read/39270812/janus-kinase-inhibitors-in-rheumatoid-arthritis-associated-interstitial-lung-disease-a-systematic-review-and-meta-analysis
#10
REVIEW
Javier Narváez, Martí Aguilar-Coll, Montserrat Roig-Kim, Pol Maymó-Paituvi, Judith Palacios-Olid, Joan Miquel Nolla, Dídac LLop
OBJECTIVE: The treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) remains challenging due to the scarcity of proven effective therapeutic options. This study aimed to investigate the effectiveness and safety of Janus kinase inhibitors (JAKi) in RA-ILD. METHODS: We systematically reviewed the literature to identify studies evaluating the efficacy and safety of JAK inhibitors in RA-ILD. A meta-analysis was performed using the random-effects model...
September 11, 2024: Autoimmunity Reviews
https://read.qxmd.com/read/39267913/evaluation-of-fibroblast-activation-protein-specific-pet-ct-in-a-patient-with-post-covid-pneumonitis
#11
JOURNAL ARTICLE
Khaled Musameh, Shane O'Brien, Roshane Mehboob, Thomas Butler, Zara Cunningham, Carol Buckley, Armin Atzinger, Torsten Kuwert, Patrick Mitchell, Seamas C Donnelly
Coronavirus disease 2019 (COVID-19) often leads to a spectrum of pulmonary complications, including interstitial lung disease (ILD) with the potential for fibrotic sequelae. Assessing the presence of ongoing active inflammation versus established residual fibrosis as a result of lung parenchymal injury and repair in these patients is a clinical challenge. Better understanding of the disease process is crucial for guiding appropriate therapeutic strategies. We aim to investigate the use of positron emission tomography / computer tomography (PET/CT) scans and their role in diagnosing interstitial pneumonitis (IP) post COVID infections...
September 2024: Respirology Case Reports
https://read.qxmd.com/read/39266479/-establishment-of-nano-ito-induced-rat-model-of-indium-lung-disease-and-exploration-of-its-pathological-characteristics
#12
JOURNAL ARTICLE
X Y Qu, W K Li, Y Z Zhao, Y Q Lin, X R Li, X Y Chen, Y Guan, Y Yu, L Xue, N Liu
Objective: To study the dynamic pathological characteristics of lung tissue in a Nano-ITO induced rat model of indium lung disease and to guide clinical and basic scientific research to further explore the mechanisms of pulmonary interstitial injury and pulmonary alveolar proteinosis (PAP). Methods: Dose-response (three divided doses) and time-course studies (six exposure periods) were performed to investigate the pulmonary toxicity induced by Nano-ITO. At the end of the experiment, cytokine levels and oxidative stress were analyzed in the bronchoalveolar lavage fluid...
September 12, 2024: Chinese Journal of Tuberculosis and Respiratory Diseases
https://read.qxmd.com/read/39266041/alveolar-capillary-dysplasia-complicated-by-subglottic-stenosis
#13
JOURNAL ARTICLE
Kotaro Nagamoto, Hidehiko Maruyama, Akira Ishuguro, Yushi Ito
Alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV) is an interstitial lung disease. In ACDMPV, respiratory impairment with severe pulmonary hypertension occurs from the early hours of life. Anomalies in the cardiovascular, gastrointestinal and genitourinary systems have been reported. However, little is known about upper airway abnormalities. We encountered a genetically diagnosed ACDMPV infant who presented with subglottic and bronchial stenosis. The prenatal diagnosis was hypoplastic left heart syndrome...
September 12, 2024: BMJ Case Reports
https://read.qxmd.com/read/39265600/mirtazapine-to-alleviate-severe-breathlessness-in-patients-with-copd-or-interstitial-lung-diseases-better-b-an-international-multicentre-double-blind-randomised-placebo-controlled-phase-3-mixed-method-trial
#14
JOURNAL ARTICLE
Irene J Higginson, Sarah T Brown, Adejoke O Oluyase, Peter May, Matthew Maddocks, Massimo Costantini, Sabrina Bajwah, Charles Normand, Claudia Bausewein, Steffen T Simon, Karen Ryan, David C Currow, Miriam J Johnson, Simon P Hart, Hannah Mather, Malgorzata Krajnik, Silvia Tanzi, Luca Ghirotto, Charlotte E Bolton, Piotr Janowiak, Elena Turola, Caroline J Jolley, Geraldine Murden, Andrew Wilcock, Bobbie Farsides, Julia M Brown
BACKGROUND: Breathlessness frequently becomes severe among people with respiratory disease. Mirtazapine, a widely used antidepressant, has shown promise in the modulation of respiratory sensation and the response to it, as well as reducing feelings of panic, which often accompanies breathlessness. We aimed to determine the effectiveness of mirtazapine to alleviate severe persisting breathlessness. METHODS: This international, multicentre, phase 3, parallel-group, double-blind, randomised, placebo-controlled trial across 16 centres in seven countries (Australia, Germany, Ireland, Italy, New Zealand, Poland, and the UK), recruited adults with chronic obstructive pulmonary disease (COPD), interstitial lung diseases, or both, and grade 3 or 4 of the modified Medical Research Council breathlessness scale...
September 6, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/39264397/practice-review-pharmacological-management-of-severe-chronic-breathlessness-in-adults-with-advanced-life-limiting-diseases
#15
REVIEW
Steffen T Simon, Irene J Higginson, Claudia Bausewein, Caroline J Jolley, Sabrina Bajwah, Matthew Maddocks, Carolin Wilharm, Adejoke O Oluyase, Anne Pralong
BACKGROUND: Severe and refractory chronic breathlessness is a common and burdensome symptom in patients with advanced life-limiting disease. Its clinical management is challenging because of the lack of effective interventions. AIM: To provide practice recommendations on the safe use of pharmacological therapies for severe chronic breathlessness. DESIGN: Scoping review of (inter)national guidelines and systematic reviews. We additionally searched for primary studies where no systematic review could be identified...
September 12, 2024: Palliative Medicine
https://read.qxmd.com/read/39263798/clinical-manifestations-treatment-and-prognosis-of-juvenile-idiopathic-arthritis-with-pulmonary-involvement-in-china-a-single-centre-study
#16
JOURNAL ARTICLE
Fengqiao Gao, Junmei Zhang, Jianghong Deng, Weiying Kuang, Xiaohua Tan, Chao Li, Shipeng Li, Xuanyi Liu, Caifeng Li
OBJECTIVES: In recent years, the distinct clinical presentations and elevated mortality rates of various subtypes of juvenile idiopathic arthritis (JIA) with pulmonary involvement have garnered significant attention. This study aimed to elucidate the clinical characteristics of pulmonary involvement in patients with JIA to improve clinicians' knowledge. METHODS: This single-centre retrospective study analysed the baseline data, treatment options, follow-up of sixty patients of JIA with pulmonary involvement in China...
September 9, 2024: Clinical and Experimental Rheumatology
https://read.qxmd.com/read/39261812/cepharanthine-attenuates-pulmonary-fibrosis-via-modulating-macrophage-m2-polarization
#17
JOURNAL ARTICLE
Jiaqi Bao, Chang Liu, Huafeng Song, Zheying Mao, Wenxin Qu, Fei Yu, Yifei Shen, Jingjing Jiang, Xiao Chen, Ruonan Wang, Qi Wang, Weizhen Chen, Shufa Zheng, Yu Chen
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a group of chronic interstitial pulmonary diseases characterized by myofibroblast proliferation and extracellular matrix (ECM) deposition. However, current treatments are not satisfactory. Therefore, more effective therapies need to be explored. Cepharanthine (CEP) is a naturally occurring alkaloid that has recently been reported to have multiple pharmacological effects, particularly in chronic inflammation. METHODS: For in vivo experiments, first, a pulmonary fibrosis murine model was generated via tracheal injection of bleomycin (BLM)...
September 11, 2024: BMC Pulmonary Medicine
https://read.qxmd.com/read/39261570/prognostic-impact-of-interstitial-lung-disease-on-pulmonary-high-grade-neuroendocrine-carcinoma
#18
JOURNAL ARTICLE
Takashi Sakai, Yoko Azuma, Megumi Kusano, Shumpei Kato, Satoshi Koezuka, Akira Iyoda
Pulmonary high-grade neuroendocrine carcinomas (HGNECs) have poor prognoses and require multimodal treatment, and interstitial lung disease (ILD) restricts sufficient treatment of patients with lung cancer. We aimed to clarify ILD's prognostic impact on pulmonary HGNEC, which has previously gone unreported. We retrospectively analyzed 53 patients with HGNEC who underwent resections at our department between 2006 and 2021 and evaluated the clinicopathological prognostic features, including ILD. The patients' mean age was 70 years; 46 (87%) were male, and all were smokers...
September 11, 2024: Scientific Reports
https://read.qxmd.com/read/39261509/comprehensive-analysis-of-scrna-seq-and-bulk-rna-seq-reveals-ubiquitin-promotes-pulmonary-fibrosis-in-chronic-pulmonary-diseases
#19
JOURNAL ARTICLE
Zhuman Wen, Abduxukur Ablimit
It is estimated that there are 544.9 million people suffering from chronic respiratory diseases in the world, which is the third largest chronic disease. Although there are various clinical treatment methods, there is no specific drug for chronic pulmonary diseases, including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Therefore, it is urgent to clarify the pathological mechanism and medication development. Single-cell transcriptome data of human and mouse from GEO database were integrated by "Harmony" algorithm...
September 11, 2024: Scientific Reports
https://read.qxmd.com/read/39260921/the-spectrum-of-systemic-sclerosis-associated-pulmonary-hypertension-insights-from-the-aspire-registry
#20
JOURNAL ARTICLE
Howard Smith, A A Roger Thompson, Mohammed Akil, Samer Alabed, Athanasios Charalampopoulos, Krit Dwivedi, Charlie A Elliot, Abdul Hameed, Ashraful Haque, Neil Hamilton, Catherine Hill, Judith Hurdman, Rachael Kilding, Kar-Ping Kuet, Smitha Rajaram, Alexander M K Rothman, Andrew J Swift, James M Wild, David G Kiely, Robin Condliffe
BACKGROUND: There are limited data assessing the spectrum of systemic sclerosis-associated pulmonary hypertension (PH). METHODS: Data for 912 systemic sclerosis patients assessed between 2000 and 2020 were retrieved from the Assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre (ASPIRE) registry and classified based on 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines and multimodality investigations...
October 2024: Journal of Heart and Lung Transplantation
keyword
keyword
12234
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.